A Cryptococcus neoformans var. grubii strain, NUBS14020, was the first fluconazole (FLZ)-resistant strain isolated from a feline cryptococcosis. Subsequent work demonstrated that multi-azole-resistant strains are readily isolated from FLZ-resistant strains by culturing in medium containing voriconazole (VRZ). The resulting clones were assessed for mutation and expression of known target genes, including the loci encoding lanosterol 14-α demethylase (ERG11), an ATP-binding cassette (ABC) transporter (AFR1), or a multidrug efflux pump (MEP); mutation and/or overexpression of these genes is known to be associated with azole resistance. We also examined the interaction between an efflux blocker (FK506, calcineurin inhibitor) and VRZ in the multi-azole-resistant strains. The ERG11 genes from multi-azole-resistant strains encoded a protein with a G344S substitution. Expression levels of AFR1, ERG11, and MEP in the multi-azole-resistant strains were not higher than those in the VRZ-susceptible parent strain (NUBS14020) when cultured in Sabourad's dextrose broth containing VRZ. Synergistic effects between FK506 and VRC were observed in all of the multi-azole-resistant strains. The minimal inhibitory concentrations (MICs) of the combination of VRZ and FK506 in multi-azole-resistant strains were 4 to 8 times lower that the MICs of VRZ alone. To the best of our knowledge, this work represents the first report that multi-azole-resistant strains of C. neoformans encode a G344S substitution in Erg11p. Further investigation will be needed to determine the mechanism of multi-azole resistance in C. neoformans, given that feline cryptococcosis due to multi-azole-resistant strains is readily transmitted from cats to humans.
Introduction
Cryptococcus is a common source of systemic mycoses in cats and zoonotic fungal infections. 1 Feline cryptococcosis is generally treated with azoles, such as fluconazole (FLZ) and itraconazole (ITZ), which are effective against human and animal cryptococcoses and have few side effects. [1] [2] [3] Isolates from human cryptococcoses have been reported to exhibit FLZ resistance. [4] [5] [6] Resistance to this azole often results from mutation of the lanosterol 14-α demethylaseencoding gene (ERG11) or overexpression of genes encoding an ATP binding cassette (ABC) trasporter (AFR1) or multi-drug-resistance protein 1 (MDR1). [4] [5] [6] [7] In a previous report, we described the first isolation of a FLZ-resistant C. neoformans var. grubii strain from a feline cryptococcosis. This strain (designated NUBS14020) exhibited a FLZ minimum inhibitory concentration (MIC) of 128 μg/ml and was susceptible to amphotericin B (AMB), ITZ, voriconazole (VRZ), and posaconazole (POZ). 8 Real-time quantitative polymerase chain reaction (RT-qPCR) analysis suggested that resistance in strain NUBS14020 is due to the overexpression of the endogenous ERG11 and AFR1 genes.
In the present study, we induced multi-azole resistance in the FLZ-resistant NUBS14020 strain and then investigated mutation and expression of the ERG11, AFR1, and multidrug efflux pump-encoding (MEP) genes of the resulting clones. Moreover, we examined the interaction between efflux blocker FK506 (a calcineurin inhibitor) and VRZ in the multi-azole-resistant isolates.
Materials and methods

Strains examined
The NUBS14020 strain of C. neoformans var. grubii was isolated from a feline case of cryptococcosis. NUBS14020 is resistant to FLZ (MIC 128 μg/ml) and susceptible to AMB (MIC 0.064 μg/ml), ITZ (MIC 0.38 μg/ml), and VRZ (MIC 0.023 μg/ml) by E-test 9 (Table 1) . Prior to study start, we confirmed that the predicted amino acid sequence of the ERG11 gene product (lanosterol 14-α demethylase) matched that of the published protein sequence (GenBank accession number: LC005248).
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Isolation of VRZ-resistant strains
Aliquots of NUBS14020 (2.3 × 10 5 yeast cells/plate) were cultured on 9-cm-diameter plates of Saboraud's dextrose agar (SDA) containing 3 μg/ml VRZ and incubated at room temperature for 7 days. Twelve individual colonies that developed on the primary selection plates were picked and isolate streaked to SDA containing 5 μg/ml VRZ, and these plates were incubated at room temperature for 10 days.
Five of the restreaked colonies demonstrated growth on the secondary selection plates; these isolates were restreaked to SDA containing 5 μg/ml VRZ, grown out for 7 days, and used for further investigation. These strains were designated NUBS14020-1 to NUBS14020-5.
Antifungal susceptibility tests
These five strains (NUBS14020-1 to NUBS14020-5) were tested for multi-azole resistance by E-test. A stock inoculum suspension for the E-test was prepared from a 3-dayold culture grown in Sabouraud's dextrose broth (SDB) at 35 • C; aliquots of the suspension were adjusted spectrophotometrically to an optical density of MacFarland 1.0 prior to testing, as described in the E-test Technical Guide 10 (SYSMEX bioMerieux Co., Ltd., Tokyo, Japan). The E-test was performed according to the manufacturer's instructions using 20 ml solidified RPMI 1640 medium with 2% dextrose in 9-cm petri plates.
The strains Candida parapsilosis ATCC 22019 and Candida kruzei ATCC 6258 were used as quality control isolates for the E-test MIC assay.
Sequence of ERG11
The ERG11 gene from each of the five VRZ-resistant strains (NUBS14020-1 to NUBS14020-5) was sequenced according to the previously described method. 8 
Real-time quantitative PCR (RT-qPCR) analysis for ERG11-, AFR1-, and multidrug efflux pump-encoding (MEP) genes
The parent and the five multi-azole-resistant strains (NUBS14020-1 to NUBS14020-5) were cultured for 3 days Table 1 . MICs (μg/ml) of antifungus drugs to the strains.
MICs were assayed by the E-test. The standard breakpoints of each azole were as follows; FLZ > 64 μg/ml, ITZ > 2 μg/ml, and VRZ > 0.5μg/ml. 5, 9, 12 at 28
• C in SDB containing 0.01 μg/ml of VRZ. Yeast cell samples were collected by centrifugation at 1600x g for 5 min, and the resulting pellets were flash-frozen in liquid nitrogen and ground to homogeneity. Total RNA was extracted from approximately 10 mg of each sample using the RNeasy total RNA kit (QIAGEN, Tokyo, Japan). Reverse transcription of the poly(A)+ RNA was performed using the OmniscriptTM Reverse Transcriptase kit (QIAGEN). The resulting cDNA samples (200 ng) were amplified by RT-qPCR (using the below primers) and analyzed as described in our previous report. 8 The gene ORFs were amplified as described in previous reports, using primer pairs as follows: AFR1 with forward primer Cnafr1-1 (5 -TCAAAACGAATACCGATTCTACCG-3 ) and reverse primer Cnafr1-2 (5 -GACCCAGAACAAGGAATCCGAC-3 );
13 ERG11 (139 bp) with forward primer RT-qPCR ERG11-5-For (5 -CCATGTCCGAGCTCATCATTCTT-3 ) and reverse primer RT-qPCR ERG11-3-Rev (5 -ACTGGGAAGGGGCAAGTTGG-3 ); 10 and actinencoding gene with forward primer Act-1 (5 -ACACTGTCCCCATTTACGAAGG-3 ) and reverse primer Act-2 (5 -CGGCAGAAGTGGTGAAGAGG-3 ). 6 A fragment (131 bp) of MEP was amplified using newly designed forward primer Cn-MDEP3F (5 -CCAGAAAGAAGATGCTTTCCCTTC -3 ) and reverse primer CnMDEP3R (5 -ATTTTCCTCAGGTTCGCGCTCATGG-3 ), corresponding to nucleotides (nt) 64-87 and 241-265 (respectively) of the Cryptococcus neoformans var. grubii H99 multidrug efflux pump (MEP) mRNA sequence of Genbank accession no. XM 012193743.
Drug interaction in susceptibility tests
Drug interaction in susceptibility tests was examined according to the CLSI protocol M27-A3 microdilution technique 11 and was evaluated using the microdilution checkerboard method. 12 The interaction between FK506
(SIGMA-Aldrich, St. Louis, MO), and VRZ was evaluated in the parent strain as well as in the five multi-azoleresistant derivatives. The concentrations of FK506 ranged from 0.03125 to 32 μg/ml, and the concentrations of VRZ ranged from 0.03125 to 32 μg/ml. The experiment was performed in triplicate. The fractional inhibitory concentration (FIC) was calculated for each agent by dividing the MIC of each drug in the combination by the MIC of the drug alone. The FIC values were then totaled to determine the fractional inhibitory concentration index (FICI) that resulted from the drug combination, using the following equation: FICI = FIC A + FIC B = Figure 1 . Comparison of the homologous regions of the predicted protein sequences encoded by the ERG11 loci of C. neoformans var. grubii strain H99 (GenBank AY376725), NUBS14020 (LC005248), multiazole-resistant strain NUBS14020-1 (LC144966), multi-azole-resistant strain NUBS14020-2, multi-azole-resistant strain NUBS14020-3, multiazole-resistant strain NUBS14020-4 and multi-azole-resistant strain NUBS14020-5. An asterisk indicates identity with the amino acid found in the Erg11p of strain H99. 
Results
MICs of strains
Minimum inhibition concentrations (MICs) were determined by the E-test after 48-h incubation at 35
• C. The five derivative strains (NUBS14020-1 to NUBS14020-5) exhibited MICs of >256 μg/ml of FLZ, > 32μg/ml of ITZ, and 6-12 μg/ml of VRZ ( Table 1 ), indicating that these strains were multi-azole resistant, consistent with previous reports.
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G344S mutations in ERG11
Basic Local Alignment Search Tool (BLAST) analysis in National Center for Biotechnology Information (NCBI) showed that the ERG11 locus of each of the 5 multi-azoleresistant strains encoded a Ser at codon 344 compared to the Gly encoded by the ERG11 loci of the reference strains C. neoformans var. grubii (GenBank accession no. AY376725) and NUBS14020 (GenBank accession no. LC005248) (Fig. 1) . The sequences determined in this study have been deposited in GenBank (Cryptococcus neoformans var. grubii NUBS14020-1 cytochrome P450 lanosterol 14α-demethylase (ERG11) gene, complete cds; GenBank accession no. LC144966).
Expression levels of AFR1, ERG11, and MEP
The mean transcript accumulation levels of AFR1 and ERG11 did not appear to differ between the parent and the multi-azole-resistant strains when cultured in SDB containing 0.01 μg/ml VRZ (Fig. 2) . The expression levels of MEP in 2 of the multi-azole resistance strains (NUBS14020-1 and 4) were similar to or lower than those in the parent strain (NUBS14020). RT-qPCR analysis of AFR1, ERG11, and MEP expression indicated the levels of these transcripts were not elevated in the multi-azole-resistant strains compared to those in the FLZ-resistant parent strain.
FK506 and VRZ interaction for azole-resistant strains
The antifungal activities of VRZ and FK506, alone and in combination, were tested in NUBS14020 and the five multi-azole-resistant derivatives after 48 h of incubation at 35
• C. The MICs for 90% inhibition (MIC90s) for each drug alone or in combination were determined in the parent and in each derivative as the median of three independent experiments, and the results are provided in Table 2 . Although FK506 exhibited limited antifungal activity on its own, the combination of FK506 with VRZ yielded (for all strains examined) MICs below those seen with VRZ alone. Notably, while the multi-azole-resistant strains exhibited MICs of 4 μg/ml of VRZ alone, the inclusion of FK506 potentiated the VRZ MIC to <1 μg/ml, such that VRZ FICI values ranged from 0.141 to 0.375 (Table 2 ). For comparison, NUBS14020 exhibited an MIC of 0.05 μg/ml of VRZ alone and of <0.0125 μg/ml of VRZ in the presence of FK506, corresponding to FICI values of 0.254 (Table 2) . Considered together, these results suggested that the combination of VRZ and FK506 exerted synergy against both the parent strain and the multi-azole-resistant derivatives ( Table 2 ).
Discussion
In this study, the multi-azole-resistant strains were readily isolated from NUBS14020, a FLZ-resistant strain of C. neoformans var. grubii. This observation indicates the importance of avoiding the overgrowth of multi-azoleresistant strains during in vivo treatment with VRZ. Feline cryptococcosis due to multi-azole-resistant yeasts is extremely dangerous for humans, since the infection can readily be transmitted as a zoonosis from cats to humans. 1 Resistance mediated by changes in the ERG11 (aka CYP51) locus, encoding a known target of azoles, has been widely documented to involve point mutation and/or overexpression of these genes. 4 The overexpression mechanism results in the accumulation of Erg11p protein and the activation of azole efflux pumps (e.g., Abc1p (an ABC transporter) and Mepp (a multidrug efflux pump)), whose activities in turn prevent the accumulation of azoles in yeast cells. 4 14 demonstrated that resistance to VRZ reflected increased efflux activity along with the acquisition of a missense mutation in the gene encoding the target enzyme Erg11p.
To understand the mechanism in our multi-azoleresistance strains, we sequenced the ERG11 gene from each of these strains and detected a mutation in the predicted amino acid sequence (G344S) of the protein encoded by ERG11. To the best of our knowledge, this work is the first report that multi-azole-resistant C. neoformans strains contain a G344S mutation in ERG11.
We also noted that the expression levels of AFR1, ERG11, and MEP were not elevated in multi-azoleresistant strains compared to those in the VRZ-susceptible parent strain (NUBS14020) when cultured in SDB containing VRZ. Therefore, these results also suggested that point mutation of ERG11 induces multi-azole resistance in C. neoformans.
The synergistic effects between the efflux blocker FK506 and VRZ were detected in all five of the multi-azoleresistant strains. The MICs of VRZ in combination with FK506 were 4 to 8 times lower in the multi-azole-resistant strains compared to those of the single VRZ MICs. Considered together, these results revealed that the combination of an efflux blocker and an azole is effective in controlling multi-azole-resistant strains of C. neoformans. Therefore, efflux blockers may provide a new antifungal drug modality for the treatment of multi-azole-resistant strains of C. neoformans.
Further investigation will be needed to optimize the treatment of multi-azole-resistant strains of C. neoformans. Such work is critical, because feline cryptococcosis is readily transmitted from cats to humans, making the infection due to multi-azole-resistant strains extremely dangerous to humans.
